SEARCH:   Advanced

Blood, 15 November 2007, Vol. 110, No. 10, pp. 3656-3661. Prepublished online as a Blood First Edition Paper on August 22, 2007; DOI 10.1182/blood-2007-05-088062. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-05-088062v1 110/10/3656    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Donfield, S. M. Articles by Gomperts, E. D. Search for Related Content PubMed PubMed Citation Articles by Donfield, S. M. Articles by Gomperts, E. D. Related Collections Hemostasis, Thrombosis, and Vascular Biology Immunobiology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Delays in maturation among adolescents with hemophilia and a history of inhibitors Sharyne M. Donfield1, Henry S. Lynn2, Alice E. Lail1, W. Keith Hoots3, Erik Berntorp4, Edward D. Gomperts5, for the Hemophilia Growth and Development Study Group 1 Department of Biostatistics, Rho, Chapel Hill, NC; 2 Department of Biostatistics, Fudan University, Shanghai, China; 3 Gulf States Hemophilia and Thrombophilia Center, Houston Medical Center, Houston, TX; 4 Department for Coagulation Disorders, Malmö University Hospital, Malmö, Sweden; and 5 Saban Research Institute, Childrens Hospital, Los Angeles, CA Inhibitory antibodies to factors VIII or IX have the potential to affect a broad range of outcomes among people with hemophilia; however, their possible effect on growth and maturation has not been explored. We evaluated skeletal maturation (bone age), pubertal progression, serum testosterone levels, height velocity, and stature in the multicenter Hemophilia Growth and Development Study. A total of 333 children and adolescents (mean age, 12.4 years) were enrolled from 1989 to 1990 and followed for 7 years. Of these, 18% (n = 60) had a history of inhibitors. Bone age among HIV– adolescents with a history of inhibitors lagged 9 or more months behind those without inhibitors at every age from 12 to 15 years. Those with a history of inhibitors were older at every Tanner stage transition, attained a lower maximum growth velocity, and their serum testosterone levels were significantly lower compared with those without inhibitors. Delays were greater among HIV+ patients with a history of inhibitors compared with those without inhibitors; however, the differences were generally small and not statistically significant. The results of this investigation underscore the importance of monitoring the growth and maturation of children and adolescents with hemophilia, particularly those with inhibitors. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020